Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs.
D000970:Antineoplastic Agents / Q000378:metabolism*; D001224:Aspartic Acid / Q000031:analogs & derivatives / Q000378:metabolism; D001761:Bleomycin / Q000378:metabolism; D002945:Cisplatin / Q000378:metabolism; D003520:Cyclophosphamide / Q000378:metabolism; D004317:Doxorubicin / Q000378:metabolism; D005472:Fluorouracil / Q000378:metabolism; D005708:Gallium / Q000378:metabolism; D006801:Humans; D007674:Kidney Diseases / Q000378:metabolism*; D007700:Kinetics; D008107:Liver Diseases / Q000378:metabolism*; D008657:Metabolic Clearance Rate; D008727:Methotrexate / Q000378:metabolism; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives / Q000378:metabolism; D011485:Protein Binding; D005641:Tegafur / Q000378:metabolism
D000970:Antineoplastic Agents; D001761:Bleomycin; D005641:Tegafur; D001224:Aspartic Acid; C013195:sparfosic acid; D004317:Doxorubicin; D003520:Cyclophosphamide; D005708:Gallium; D010746:Phosphonoacetic Acid; D002945:Cisplatin; D005472:Fluorouracil; C027235:gallium nitrate; D008727:Methotrexate